Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers

Commentary
Podcast

Drs Monk and Tarantino highlight current research investigating B7-H4–directed antibody-drug conjugates. in multiple solid tumor types.

Welcome to OncLive On Air®! I’m your host today, Courtney Flaherty.

OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, sponsored by Seagen, we had the pleasure of speaking with Bradley J. Monk, MD, FACOG, FACS, and Paolo Tarantino, MD, about several ongoing and planned tumor-agnostic trials evaluating antibody-drug conjugates (ADCs) with novel targets in breast and gynecologic cancers.

Dr Monk is a gynecologic oncologist and the medical director of the Late-Stage Clinical Research Program at Florida Cancer Specialists & Research Institute in West Palm Beach. Dr Tarantino is a researcher at the European Institute of Oncology in Milan, Italy, as well as a clinical research fellow at Dana-Farber Cancer Institute in Boston, Massachusetts.

One emerging target of note is B7-H4 vedotin. The investigational B7-H4 vedotin–directed ADCs SGN-B7H4V and HS-20089 are being evaluated in respective phase 1 trials (NCT05194072; NCT05263479) in patients with advanced solid tumors. These agents have generated early efficacy signals in their respective trials.

In our exclusive interview, Drs Monk and Tarantino highlight current research investigating B7-H4–directed ADCs, including SGN-B7H4V and HS-20089, in multiple solid tumor types; spotlighted several other promising ADCs in early development for gynecologic cancers; and speculated on future research needed to clarify unanswered questions regarding the optimal use and sequencing of ADCs in breast cancer.

___

That’s all we have for today! Thank you for listening to this episode of OncLive On Air, sponsored by Seagen. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive is also on social media. On Twitter, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air.

*OncLive On Air is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.

Related Videos
Reshma Jagsi, MD, DPhil, Emory University
Jane L. Meisel, MD
Kari Wisinski, MD, Endowed Professor of Hematology and Oncology, chief, Division of Hematology, Medical Oncology, and Palliative Care, Department of Medicine, University of Wisconsin (UW) School of Medicine and Public Health; associate director, Clinical Research, co-lead, Breast Cancer Disease Oriented Team, UW Carbone Cancer Center
A panel of 4 experts on chronic graft-versus-host disease
A panel of 4 experts on chronic graft-versus-host disease
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD